ChargePoint Technology invests in production capabilities for large-scale containment valves
The new 5-axis machine will speed up the production and delivery of larger diameter valves up to 350 mm.
Powder containment and aseptic transfer valve specialist ChargePoint Technology has invested in new manufacturing machinery at its UK facility to meet increased demand for larger diameter valves for use in large-scale drug manufacturing that requires containment.
The new 5-axis machine is the first of its kind in the UK and forms part of a wider £1 million investment into advanced manufacturing capabilities at the company’s facility in Liverpool. It will enable ChargePoint Technology to speed up the production and delivery of larger diameter valves up to 350 mm (14”).
The investment has been made in response to growing containment demands that are being driven by growth within therapeutic areas, including oncology and hormonal drug products. This is leading to increased volumes of high potency active pharmaceutical ingredients (HPAPIs) being used in the production of tablets, capsules and other solid dosage forms.
Tony O’Sullivan, chief commercial officer at ChargePoint Technology, commented: “We are seeing an increase in demand from solid dose manufacturing companies, including big pharma firms and CMOs in the US and Europe, for large-scale containment valve solutions.
“Our new machinery enables us to manufacture larger diameter valves, directly addressing this market need. In addition, our in-house manufacturing strategy provides us with absolute control over the quality of the final product so our customers can rest assured that they receive high-performing and reliable technology.
“Growth in the high-volume manufacture of generics, particularly in Asia, is also driving demand for larger containment valves, as there is a need to upgrade existing process equipment to safely replicate the production of higher potency off patent drugs, while ensuring drug quality and operator safety. We expect this segment to grow in the future as the pharmaceutical landscape evolves.”
As part of the investment, a new automated washing plant will be used to ensure effective and repeat cleaning of parts with higher throughput capacity, while a new 3-axis coordinate measuring machine (CMM) will also allow for high precision measurement and scanning of critical valve components in-house.
ChargePoint Technology intends to invest further in manufacturing capabilities at its facility over the next 3 years. In particular, it plans to continue to evolve its product design using the latest manufacturing methods to provide further advancements in valve technology.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance